Journal of Surgical Oncology最新文献

{"title":"Sexual Health in Postmastectomy Breast Reconstruction Patients and Value of an Intervention: A Qualitative Study.","authors":"Minji Kim, Jaime L Gilliland, Charles Z Jiang, Mei-Fan Parnes, Jeanne Carter, Audree B Tadros, Babak J Mehrara, Jonas A Nelson, Carrie S Stern","doi":"10.1002/jso.70056","DOIUrl":"10.1002/jso.70056","url":null,"abstract":"<p><strong>Background: </strong>In this qualitative study, we assessed patients' perception of how postmastectomy breast reconstruction (PMBR) impacts sexual health and the perceived value of consultations with the sexual medicine team.</p><p><strong>Methods: </strong>PMBR patients were recruited for four focus groups, two with patients who had sexual medicine consultations and two with patients who did not. Patients completed two surveys, BREAST-Q Sexual Well-being and Patient-Reported Outcomes Measurement Information System (PROMIS) Sexual function and satisfaction (SexFS). Focus groups were audio-taped, transcribed, and analyzed thematically.</p><p><strong>Results: </strong>There were 35 participants, 17 patients who received sexual medicine consultations and 18 patients who did not. The median Sexual Well-being score was 48 (Interquartile range: 31, 53) and PROMIS SexFS scores were lower than the United States adults' scores. Analysis identified six major themes: (1) patient experience of physical and nonphysical impacts of diagnosis and treatment that lead to a decline in sexual health, (2) utilization of clinical and nonclinical strategies to address sexual health concerns, (3) patient perception of importance of sexual health and how it is often overlooked in oncology care broadly and in plastic surgery specifically, (4) desired information about sexual health, (5) patient desire for a dedicated place to discuss their sexual health concerns, and (6) desired aspects of sexual medicine consultations.</p><p><strong>Conclusion: </strong>Patients perceive a decline in their sexual health as a result of breast cancer diagnosis and treatment, with specific challenges associated with PMBR. Patients desire a dedicated space to discuss sexual health concern, and sexual medicine consultations are one possible approach.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment On: “Clinical Course After Radical Local Therapy for Oligo-Recurrence of Nonsmall Cell Lung Cancer”","authors":"Seyed Esmaeil Mousavi,&nbsp;Danyal Yarahmadi","doi":"10.1002/jso.28153","DOIUrl":"10.1002/jso.28153","url":null,"abstract":"","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"132 3","pages":"405-406"},"PeriodicalIF":1.9,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multisocietal Consensus on the use of Cytoreductive Surgery and HIPEC for the Treatment of Pseudomyxoma Peritonei: A GRADE Approach for Evidence Evaluation and Recommendation.","authors":"Shigeki Kusamura, Edward Levine, Michela Cinquini, Olivier Glehen, Pompiliu Piso, Andreas Brandl, Claudio Quadros, Marc Pocard, Faheez Mohamed, Clarice Eveno, Dario Baratti, Marcello Guaglio, Marcello Deraco, Brendan Moran","doi":"10.1002/jso.28167","DOIUrl":"https://doi.org/10.1002/jso.28167","url":null,"abstract":"<p><strong>Introduction: </strong>Pseudomyxoma peritonei (PMP) is a rare malignancy characterized by mucinous ascites and peritoneal implants, primarily arising from ruptured appendiceal neoplasms. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has become the preferred treatment for resectable and operable cases.</p><p><strong>Methods: </strong>An international panel from the Peritoneal Surface Oncology Group International (PSOGI), the International Society for the Study of Pleura and Peritoneum (ISSPP), the Society of Surgical Oncology (SSO), the European Society of Surgical Oncology (ESSO), and EURACAN used the GRADE methodology and ADOLOPMENT approach to adapt existing guidelines. Clinical questions were framed using the PICO framework, and systematic reviews were conducted. Evidence certainty and the balance of benefits and harms were evaluated with the Evidence-to-Decision framework.</p><p><strong>Results: </strong>A strong recommendation was made for CRS and HIPEC over debulking surgery for resectable PMP. Observational studies reported 5- and 10-year survival rates of 80% and 55%, respectively, with CRS and HIPEC, compared to lower outcomes with debulking. Despite the very low certainty of evidence, the panel strongly endorses CRS and HIPEC over debulking surgery. This recommendation is driven by PMP's known chemoresistance, the lack of viable alternative treatments, and the survival benefits observed in observational studies coming only from radical surgery.</p><p><strong>Conclusion: </strong>This consensus endorses CRS and HIPEC as the standard of care for operable and resectable PMP. This recommendation will increase acceptance and awareness among a broader audience of healthcare professionals about the potential benefits of this treatment in managing this rare peritoneal disease.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Laparoscopic and Robotic Liver Resection in Elderly Patients: A NSQIP Analysis of Short-Term Outcomes.","authors":"Alessandro Parente, Kevin Verhoeff, Mohamed Elmasry, Blaire L Anderson, Khaled Z Dajani, Parthi Srinivasan, A M James Shapiro, Krishna V Menon","doi":"10.1002/jso.70065","DOIUrl":"https://doi.org/10.1002/jso.70065","url":null,"abstract":"<p><strong>Introduction: </strong>Results of minimally invasive laparoscopic (LLR) and robotic liver resection (RLR) have been promising, but the benefits in the elderly patients are still unclear. This study aims to compare short-term outcomes of LLR and RLR in elderly patients.</p><p><strong>Methods: </strong>The 2017-2021 NSQIP database was analyzed comparing patients ≥ 65 years old undergoing LLR versus RLR. Postoperative outcomes, factors associated with complications and mortality were assessed using propensity score matched (PSM) and multivariable logistic regression.</p><p><strong>Results: </strong>We analyzed 2,210 patients undergoing LLR (n = 1865,84.4%) and RLR (n = 345,15.6%). Patients undergoing LLR were older (72.4 vs. 71.8 years; p = 0.04) and more likely to have ASA 4 (11.1% vs. 4.9%; p = 0.001). RLR patients had shorter hospital stays (3.5 vs. 4.4 days; p < 0.001) but longer operative durations (221.4 vs. 203.5 min; p = 0.013). On adjusted analyses, RLR was not associated with increased odds of serious complications (OR: 0.82, CI95% 0.42-1.58, p = 0.545) or mortality (OR: 0.87, p = 0.851). After PSM, RLR statistically reduced length of stay (-0.72 days; p = 0.012) but increased operative times ( + 32.62 min; p < 0.001). Subgroup analysis of patients ≥ 75 years confirmed consistent findings.</p><p><strong>Conclusions: </strong>RLR provides comparable safety and short-term outcomes to LLR, offering shorter hospital stays but longer operative durations. Findings support RLR as a viable option in elderly patients, but further studies evaluating long-term outcomes are warranted.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144847150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathologic Factors Influencing Endoscopic Versus Surgical Approaches in Patients With T1b Gastric Carcinoma With Lymphoid Stroma.","authors":"Sun Mi Lee, Ji Young Kim","doi":"10.1002/jso.70053","DOIUrl":"https://doi.org/10.1002/jso.70053","url":null,"abstract":"<p><strong>Background: </strong>Pathologic T1b (pT1b) gastric carcinoma with lymphoid stroma (GCLS) has been proposed as a potential candidate for endoscopic resection due to reported low rates of lymph node metastasis (LMN). Evaluation of the clinicopathological factors associated with the risk of LNM may lead to improved treatment options for patients with pT1b GCLS.</p><p><strong>Methods: </strong>A retrospective cohort analysis examined 102 patients with resected pT1b GCLS from 2012 to 2022. Patients with pT1b gastric adenocarcinoma (GAC) served as the control group. We investigated the clinicopathologic factors associated with the risk of LNM and potential morbidities related to endoscopic approaches in patients with T1b GCLS.</p><p><strong>Results: </strong>Of the 102 patients with pT1b GCLS, 88.2% had positive Epstein-Barr virus (EBV) tests. Tumors were located in the upper stomach in 20.6% of pT1b GCLS patients, with a median submucosal invasion depth of 1430 µm. LNM was identified in 11.8% of these patients (each, p < 0.01). In comparison, among the 143 patients with pT1b GAC, only 0.7% had positive EBV tests. Tumors were located in the upper stomach in 5.6% of these patients, with a median submucosal invasion depth of 700 µm, and 20.3% of GAC patients had LNM.</p><p><strong>Conclusions: </strong>Considering the higher rates of deeply invading submucosal tumors and of LNM, our study suggests that surgical approaches should remain the standard recommended therapy for patients with pT1b GCLS.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144847149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving Trends in Postmastectomy Breast Reconstruction With Autologous Tissues: A Large-Scale, 24-Year Retrospective Study in China.","authors":"Xuliren Wang, Zhibo Shao, Han Zhu, Qi Zhang, Jiajian Chen, Yingying Zhang, Ayong Cao, Yi Zhang, Rui Xu, Jingyan Xue, Jing Liu, Miao Mo, Zhi-Ming Shao, Bingqiu Xiu, Jiong Wu, Shuang Hao","doi":"10.1002/jso.70059","DOIUrl":"https://doi.org/10.1002/jso.70059","url":null,"abstract":"<p><strong>Background: </strong>Autologous breast reconstruction (ABR) significantly improves quality of life following mastectomy. However, ABR has traditionally been underutilized compared to implant-based breast reconstruction (IBBR), partly due to its technical complexity, longer operative time, and relatively limited reimbursement. This study aimed to evaluate the patterns and evolving trends of ABR in China.</p><p><strong>Methods: </strong>Annual trends in breast reconstruction at Fudan University Shanghai Cancer Center (FUSCC) from 2000 to 2023 were retrospectively analyzed. Data included patient demographics, reconstruction timing, flap types, adjuvant radiotherapy status, and reoperations due to complications. Temporal trends were assessed using linear regression analysis.</p><p><strong>Results: </strong>Among 6,174 unilateral breast reconstruction cases, 2,123 (34.39%) involved ABR. Latissimus dorsi flaps (LDF) were the most commonly used technique overall (59.87%, n = 1,271), while the use of deep inferior epigastric perforator (DIEP) flaps increased markedly over time. By 2023, DIEP flaps accounted for 56.46% of all ABR procedures, becoming the predominant modality. Their rise was particularly notable in delayed and immediate-delayed reconstructions, as well as in salvage ABR following implant failure. Among patients receiving adjuvant radiotherapy, the preference for DIEP flaps also increased significantly. Both LDF and DIEP flaps demonstrated low reoperation rates, highlighting their safety and clinical reliability.</p><p><strong>Conclusions: </strong>Autologous breast reconstruction in China is shifting toward increased utilization of DIEP flaps, particularly in delayed, immediate-delayed, and implant-salvage settings, as well as among patients undergoing radiotherapy. These findings support DIEP as a preferred flap type in modern reconstructive practice.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential of Combination of CE-MRI and Serum Her-2neu Extracellular Domain in Evaluating Effectiveness of Neoadjuvant Chemotherapy in Breast Cancer.","authors":"PengFei Liu, YuanQing Liu, YuYang Xie, Su Hu, Hao Zhou, Ling Yang","doi":"10.1002/jso.70058","DOIUrl":"https://doi.org/10.1002/jso.70058","url":null,"abstract":"<p><strong>Background and objectives: </strong>The incidence and mortality rates of breast cancer continue to pose significant challenges. Neoadjuvant chemotherapy is now established as a standardized treatment for locally advanced breast cancer. Notably, a subset of breast cancer patients may attain pathological complete remission (pCR) through neoadjuvant chemotherapy (NAC). The potential to avoid surgery exists if accurate preoperative recognition of complete pathological remission is achieved. Therefore, our research is dedicated to determine the potential of the combination of contrast-enhanced magnetic resonance imaging (CE-MRI) method with the serum level of extracellular domain of human epidermal growth factor receptor-2 (Her-2neu ECD) in the evaluation of the efficacy of neoadjuvant chemotherapy in breast cancer patients.</p><p><strong>Methods: </strong>Sixty-six patients with breast cancer who received NAC in our hospital from September 2019 to July 2022 were enrolled retrospectively, and were divided into the pathological complete remission group and non-pathological complete remission (n-pCR) group based on pathological results. All patients underwent 6 to 8 cycles of NAC. Lesions were measured using CE-MRI and apparent diffusion coefficient (ADC) maps before and after NAC. Serum levels of Her-2neu ECD were measured by chemiluminescence before and after NAC. The change in tumor volume, maximum diameter and ADC values before and after NAC were calculated. Two logistic prediction model were established based on the independent predictors, and the performance of the models for predicting pCR of NAC were compared.</p><p><strong>Results: </strong>The pCR group and n-pCR group were included 30 patients (average age, 48 years) and 36 patients (average age, 48 years), respectively. Hormone receptor status (odds ratio [OR], 4.47 [95% CI: 1.40, 14.32]; p = 0.012), human epidermal growth factor receptor-2 status (OR, 0.15 [95% CI: 0.05, 0.49]; p < 0.01), tumor volume change rate (ΔTV%) during NAC (OR, 1.12 [95% CI: 1.06, 1.26]; p < 0.001), and changes in serum Her-2neu ECD levels during NAC (OR, 1.14 [95% CI: 1.05, 1.24]; p < 0.001) were independently associated with the odds of achieving pCR. The model that combined ΔTV% and ΔHer-2neu ECD showed a relatively higher performance (AUC = 0.914, [95%CI: 0.850, 0.978]) than the model included ΔTV% and Her-2 receptor (AUC = 0.894, [95%CI: 0.819, 0.970]).</p><p><strong>Conclusion: </strong>The model that combined MRI indicators and serum Her-2neu ECD levels showed a good performance for predicting pCR to NAC in patients with breast cancer.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of a Multidisciplinary Clinic on Time to Treatment for Soft Tissue Sarcoma","authors":"Britany Hollenquest,&nbsp;Kelsey Montgomery,&nbsp;Adam Lucy,&nbsp;Adam Banks,&nbsp;Vanessa Eulo,&nbsp;Kristy Broman","doi":"10.1002/jso.70061","DOIUrl":"10.1002/jso.70061","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>Delay in treatment may be associated with worse outcomes for soft tissue sarcoma, which often requires multidisciplinary management. Our objective was to evaluate the implementation of a sarcoma multidisciplinary clinic (MDC) on time to treatment initiation (TTI) at our tertiary cancer center.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with localized or metastatic soft tissue sarcoma were seen at our tertiary referral center from November 2021-January 2024 in MDC or usual care (single specialty clinic). Treatment delay was defined as greater than 50 days from initial assessment to first treatment (surgery, radiation, or systemic therapy), compared using chi-squared tests and multivariable logistic regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 275 patients, 33 were seen in MDC and 242 usual care. Median TTI was 33.0 days (interquartile range (IQR) 18–57). Eighty-two patients (29.8%) had treatment delays, with no difference for MDC (31.1%) versus usual care (15.2%) (<i>p</i> = 0.05) (adjusted odds ratio 0.39, 95% Confidence Interval 0.14–1.06). Patients evaluated in the MDC were more likely to receive multimodal therapy (75.8% vs. 41.7%, <i>p</i> &lt; 0.01) and radiation as their first treatment (54.5% vs. 27.3%, <i>p</i> &lt; 0.01).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Implementation of a MDC did not significantly reduce treatment delay but was associated with increased likelihood of multimodal therapy. Future work should evaluate TTI in cohorts with greater penetrance of MDC care and assess other oncology and patient-centered endpoints.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"132 4","pages":"763-772"},"PeriodicalIF":1.9,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multisocietal Consensus on the Use of Cytoreductive Surgery and HIPEC for the Treatment of Epithelial Ovarian Cancer: A GRADE Approach for Evidence Evaluation and Recommendation.","authors":"Donnal Brennan, Amy Hawarden, Michela Cinquini, Aditi Bhatt, Sampige Prasanna Somashekhar, Piso Pompiliu, Andreas Brandl, Edward Levine, Thanh H Dellinger, Naoual Bakrin, Sammartino Paolo, Lo Dico Rea, Dario Baratti, Guaglio Marcello, Shigeki Kusamura, Deraco Marcello","doi":"10.1002/jso.28166","DOIUrl":"https://doi.org/10.1002/jso.28166","url":null,"abstract":"<p><strong>Introduction: </strong>The locoregional treatment of high grade serous ovarian cancer (HGSOC) comprises of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Recent evidence form randomized trials, has led to controversy related to the use of HIPEC in addition to interval CRS (iCRS) and the role of secondary CRS (sCRS) in patients with the first platinum-sensitive recurrence from high-grade serous ovarian cancer (HGSOC). This multi-society consensus, coordinated by the Peritoneal Surface Oncology Group International (PSOGI) with inputs from ISSPP, SSO, ESSO, and IGCS, evaluated the role of these interventions using the GRADE ADOLOPMENT methodology.</p><p><strong>Patients and methods: </strong>An international expert panel reviewed evidence for the use of HIPEC in addition to iCRS in stage 3 high grade serous ovarian cancer (HGSOC) and the role of sCRS for patients with platinum-sensitive recurrent HGSOC. A systematic review assessed randomized controlled trials (RCTs) for recurrence-free survival (RFS), overall survival (OS), safety, and quality of life (QoL). Recommendations were formulated using the GRADE Evidence-to-Decision framework.</p><p><strong>Results: </strong>HIPEC in addition to iCRS was strongly recommended based on the results of the OVHIPEC-1 trial, which showed significant benefit in RFS (3.5 months) and OS (12 months) without increasing the grade 3-4 morbidity. For the first platinum-sensitive recurrence, a conditional recommendation was made either for sCRS with systemic therapy or systemic therapy alone, reflecting variability in trial outcomes due to heterogeneity in the patient population in the trials and lack of surgical standardization.</p><p><strong>Conclusion: </strong>This consensus highlights the benefits of HIPEC in addition of iCRS and key factors that limit its wide-spread use. It underlines the need for individualized decision-making while selecting patients for sCRS. Future research integrating advanced systemic therapies is essential to refine these recommendations and provide equitable access to these complex locoregional treatments.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144799475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing Socioeconomic Factors That Influence Treatment Selection in Myxoid Liposarcoma: A Population-Based Study From the Surveillance, Epidemiology, and End Results Database.","authors":"Kole Joachim, Adrian Lin, Brandon Gettleman, Christopher Hamad, Amanda Perrotta, Sumin Jeong, Michael Fice, Lauren E Wessel, Nicholas M Bernthal, Alexander B Christ","doi":"10.1002/jso.70064","DOIUrl":"https://doi.org/10.1002/jso.70064","url":null,"abstract":"<p><strong>Introduction: </strong>Myxoid liposarcoma (MLS) is the second most common liposarcoma, representing 6% of adult soft-tissue sarcomas. This study examines differences in treatment types and survival outcomes by income and rurality in MLS patients.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted using the Surveillance, Epidemiology, and End Results database for MLS patients from 2000 to 2021. Variables included age, sex, income, and rurality. Treatment types included surgery, chemotherapy, and radiotherapy. Time from diagnosis to treatment was compared by income and rurality. Survival was assessed using the Fine-Gray model.</p><p><strong>Results: </strong>The cohort included 2544 MLS patients: 55.6% above median income and 91.2% urban. Higher-income patients were more likely to receive radiotherapy (p < 0.001), while urban patients were more likely to undergo surgery (p < 0.001). For Grades 2 and 3 tumors, high-income patients were more likely to undergo surgery (odds ratio [OR] = 2.35; 95% confidence interval [95% CI]: 1.16-4.74, p = 0.017) and radiotherapy (OR = 1.42, 95% CI: 1.09-1.87, p = 0.010). Urban patients were also more likely to undergo surgery (OR = 2.85, 95% CI: 1.26-6.48, p = 0.012).</p><p><strong>Conclusions: </strong>In this MLS cohort, patients with higher incomes were more likely to receive radiotherapy and surgical resection for Grades 2 and 3 tumors. These findings highlight the need for risk-adapted treatment approaches to standardize interventions across socioeconomic groups.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}